Moreover, such studies may also reveal the effect of targeting subsets of HS patients based on additional parameters, including TIL density and PD-1 expression, both of which predict response to PD-1 blockade in other tumors such as melanoma [21]. The gene discussed is PDCD1; the disease is melanoma.